Latest Conference Articles

September 13th 2021, 2:51pm

American Urological Association Annual Meeting

The addition of avelumab to Bacillus Calmette-Guerin induction therapy appeared to be safe and well tolerated in patients with BCG-unresponsive non–muscle invasive bladder cancer.

September 13th 2021, 2:45pm

American Urological Association Annual Meeting

Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.

September 12th 2021, 7:41pm

American Urological Association Annual Meeting

The combination of olaparib and pembrolizumab continued to demonstrate antitumor activity in patients with metastatic castration-resistant prostate cancer who previously received docetaxel.

September 12th 2021, 7:25pm

American Urological Association Annual Meeting

Steven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.

September 12th 2021, 6:05pm

American Urological Association Annual Meeting

Darolutamide was linked with a reduction in locally invasive procedures, delayed time to deterioration in health-related quality of life related to urinary and bowel symptoms in patients with nonmetastatic castration-resistant prostate cancer.

September 12th 2021, 6:03pm

American Urological Association Annual Meeting

Enzalutamide plus androgen-deprivation therapy produced clinical benefit over ADT alone in patients with metastatic hormone-sensitive prostate cancer, regardless of prior antiandrogen therapy and its pretreatment duration.

September 12th 2021, 1:00pm

International Myeloma Society Annual Meeting

Fredrik Schjesvold, MD, PhD, discusses key takeaways from the phase 3 OCEAN trial that was done in patients with relapsed/refractory multiple myeloma.

September 12th 2021, 12:56am

International Myeloma Society Annual Meeting

Melphalan flufenamide (melflufen) plus dexamethasone demonstrated an improvement in progression-free survival vs pomalidomide/dexamethasone in patients with transplant-naïve relapsed/refractory multiple myeloma.

September 11th 2021, 7:15pm

American Urological Association Annual Meeting

Nadofaragene firadenovec, a novel intravesical gene therapy for patients with bacillus Calmette-Guérin unresponsive non–muscle invasive bladder cancer, demonstrated sustained durability according to findings from 2 cohorts of a phase 3 study.

September 11th 2021, 6:40pm

American Urological Association Annual Meeting

Relugolix failed to significantly delay onset of castration resistance compared with standard of care leuprolide in men with advanced prostate cancer.

September 11th 2021, 5:53pm

American Urological Association Annual Meeting

The combination of durvalumab and Vicineum was found to be well tolerated and to elicit complete responses in patients with Bacillus-Calmette Guérin–unresponsive non–muscle invasive bladder cancer.

September 11th 2021, 5:28pm

American Urological Association Annual Meeting

Treatment with neoadjuvant lutetium prostate-specific membrane antigen followed by radical prostatectomy exhibited a favorable safety profile in patients with locally advanced high-risk prostate cancer.

September 11th 2021, 5:21pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Existing racial and socioeconomic disparities among patients with T-cell non-Hodgkin lymphoma continue to lead to obstacles with access for newly available treatment options.

September 11th 2021, 5:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The JAK1/JAK2 inhibitor ruxolitinib has several clinical uses in the treatment of patients with polycythemia vera and plays an especially important role in adult patients who have had an inadequate response to hydroxyurea.

September 11th 2021, 3:47pm

IASLC World Conference on Lung Cancer

Frontline sequential therapy with crizotinib followed by alectinib demonstrated survival benefits for patients with ALK-positive non–small cell lung cancer who develop resistance to, or become intolerant of crizotinib.

September 11th 2021, 3:38pm

International Myeloma Society Annual Meeting

Minimal residual disease–based consolidation therapy comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone was found to induce quick responses and unprecedented rates of MRD negativity in patients with newly diagnosed multiple myeloma.

September 11th 2021, 2:43pm

American Urological Association Annual Meeting

TAR-200 plus cetrelimab may offer a superior treatment option for patients with muscle-invasive bladder cancer, and to answer this questions, investigators have initiated the randomized, phase 3 SunRISe-2 trial.

September 11th 2021, 2:15pm

American Urological Association Annual Meeting

Primary tumor response to nivolumab plus ipilimumab observed results of a Japanese study indicates a changing role for the timing of cytoreductive nephrectomy for patients with advanced renal cell carcinoma.fr

September 11th 2021, 12:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

September 11th 2021, 12:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Alexey V. Danilov, MD, PhD, discusses the need to identify novel pathways for targeted therapy in chronic lymphocytic leukemia.